GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OliX Pharmaceuticals Inc (XKRX:226950) » Definitions » Net Income From Continuing Operations

OliX Pharmaceuticals (XKRX:226950) Net Income From Continuing Operations : ₩-45,519 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is OliX Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. OliX Pharmaceuticals's net income from continuing operations for the three months ended in Mar. 2025 was ₩-13,265 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-45,519 Mil.

OliX Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for OliX Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OliX Pharmaceuticals Net Income From Continuing Operations Chart

OliX Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19,384.55 -30,277.90 -21,887.81 -19,101.70 -40,658.70

OliX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,405.03 -9,584.86 -10,506.55 -12,162.26 -13,265.12

OliX Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-45,519 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OliX Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OliX Pharmaceuticals Inc (XKRX:226950) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:950210 XKRX:347850 XKRX:005690 XKRX:085660 XKRX:005250 XKRX:358570 XKRX:115450 XKRX:086900 XKRX:053030 XKRX:048410 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 1014 Gwanggyo Ace Tower 1, Daehak 4-ro, Yeongtong-gu, Gyeonggi, Suwon, KOR, 16226
Website
http://www.olixpharma.com
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company's pipeline products include OLX101, OLX201, OLX301, OLX102, and others.

OliX Pharmaceuticals Headlines

No Headlines